A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis

Summary

This was a randomized, double blind, placebo controlled, parallel group study in 129 subjects with moderate to severe psoriasis with a PASI score of at least 10. Following run-in, subjects were randomized and received either oral 30 mg ZPL-3893787 once daily or placebo once daily for 12 weeks.

Timeline

Start

2016-01-11

Primary completion

2016-12-22

Completion

2016-12-22

Drugs

Indications